GSD On Other Exchanges
Symbol
Exchange
Venture

devonian health group inc (GSD) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DEVONIAN HEALTH GROUP INC (GSD)
\

Related News

No related news articles were found.

devonian health group inc (GSD) Related Businessweek News

No Related Businessweek News Found

devonian health group inc (GSD) Details

Devonian Health Group Inc., a pharmaceutical company, engages in the development of botanical drugs. Its lead product candidate is Thykamine, which is in Phase II clinical trials for the treatment of ulcerative colitis and atopic dermatitis. It also develops value-added products for dermo-cosmetics. The company was incorporated in 2013 and is headquartered in Québec, Canada.

Founded in 2013

devonian health group inc (GSD) Top Compensated Officers

Chairman, President, CEO & Secretary
Total Annual Compensation: C$244.3K
CFO & Corporate Controller
Total Annual Compensation: C$32.0K
Compensation as of Fiscal Year 2018.
devonian health group inc
Devonian Announces the Filing of a New Patent Application Related to Use of Thylakoids as Delivery System for Cannabinoïds and Other Liposoluble Molecules

Devonian Health Group Inc. announced that the company has filed a patent application for the use of thylakoids as delivery system for cannabinoids and other liposoluble molecules for pharmaceutical and cosmetic applications. The patent application relates to thylakoids and functional derivatives, as carriers for molecules. More specifically, this invention relates to a composition comprising functional thylakoids, particularly in specific formulations that ensure the integrity and functionality of molecules, particularly liposoluble molecules, that are difficult to formulate, to increase their bioavailability. The patent covers the extraction of cannabinoids-containing thylakoids from plant such as Cannabis sativa, indica or hemp. It also covers the incorporation of liposoluble molecules, such as cannabinoids, into thylakoids extracted from any photosynthetic organism.

Devonian Signs a Binding Letter of Intent with Histapharm Inc. to Extract and Manufacture Their Proprietary Botanical Pharmaceutical Product and to Enter into a Strategic Partnership for the Development of New Products

Devonian Health Group Inc. and Histapharm Inc. announced that they have signed a binding Letter of Intent ("LOI") to negotiate the terms establishing Devonian as the exclusive site for the extraction and manufacturing of Histapharm’s proprietary botanical drug. Histapharm’s product targets the degradation of histamine being a different approach compared to treatments using antihistamine technologies. The LOI also includes the set-up of a Strategic Partnership focused on the development of new products for dermatological applications. Under the LOI, Devonian will be the exclusive site for the extraction and manufacturing of the botanical drug containing diamine oxydase (DAO). Furthermore, under the Strategic Partnership, Devonian and Histapharm will develop new products, derived from the combination of their respective platforms, products and know-how. In order to facilitate the Partnership, Histapharm intends to set up its head office in close proximity to Devonian. The Manufacturing Agreement must be executed within the next 150 days and the Strategic Partnership by November, 30, 2019.

Devonian Health Group Inc. Announces Appointments to Advisory Board

Devonian Health Group Inc. announced that it has formed a Scientific Advisory Board comprised of experts in botany, chemistry, immunology, infectious diseases, drug discovery and development. This Scientific Advisory Board will assist Devonian’s Research and Development team in the development of cannabinoïds-based pharmaceutical drugs. The appointees are Dr. Louis Flamand, PhD, MBA (Laval University), Dr. Suha Jabaji, PhD (McGill University), Prof. Francois Malouin, PhD (Université de Sherbrooke), and Dr. John Trant, PhD (University of Windsor). Louis Flamand, PhD, MBA, is a full professor and chair of the department of microbiology-infectious-disease-immunology at the Faculty of medicine, Université Laval and senior researcher in the division of infectious and immune diseases at the CHU de Quebec research center-Université Laval. Dr. Suha Jabaji, PhD. is a molecular plant pathologist in training. She obtained her PhD from the University of Waterloo, Ontario, Canada. At the rank of full Professor in Plant Science, McGill University, her scientific contributions are recognized at the national and international levels. François Malouin is professor (microbiology) at the Department of biology at the Faculty of sciences of Universite de Sherbrooke since 2000. Dr. John Trant received his PhD from the University of Ottawa in 2012 in making antifreeze glycopeptides under the supervision of Dr. Robert Ben. After postdoctoral work with Dr. Tomas Hudlicky (natural product synthesis, Brock) and Dr. Elizabeth Gillies (polymer and nanoscience, Western) he began his own group at the University of Windsor in 2016.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

GSD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GSD.
View Industry Companies
 

Industry Analysis

GSD

Industry Average

Valuation GSD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DEVONIAN HEALTH GROUP INC, please visit www.groupedevonian.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.